{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T16:44:54Z","timestamp":1782492294947,"version":"3.54.5"},"reference-count":235,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Chest Medicine"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.ccm.2013.10.003","type":"journal-article","created":{"date-parts":[[2013,12,5]],"date-time":"2013-12-05T10:00:44Z","timestamp":1386237644000},"page":"219-239","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["New Drug Therapies for COPD"],"prefix":"10.1016","volume":"35","author":[{"given":"Clare L.","family":"Ross","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor T.","family":"Hansel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ccm.2013.10.003_bib1","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.coph.2013.03.014","article-title":"New treatments for COPD","volume":"13","author":"Ngkelo","year":"2013","journal-title":"Curr Opin Pharmacol"},{"issue":"5","key":"10.1016\/j.ccm.2013.10.003_bib2","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1378\/chest.11-2766","article-title":"Novel antiinflammatory therapies for COPD","volume":"142","author":"Gross","year":"2012","journal-title":"Chest"},{"issue":"9795","key":"10.1016\/j.ccm.2013.10.003_bib3","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/S0140-6736(11)61295-6","article-title":"Controversies in treatment of chronic obstructive pulmonary disease","volume":"378","author":"Rabe","year":"2011","journal-title":"Lancet"},{"issue":"9795","key":"10.1016\/j.ccm.2013.10.003_bib4","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/S0140-6736(11)61047-7","article-title":"The future of chronic obstructive pulmonary disease treatment\u2013difficulties of and barriers to drug development","volume":"378","author":"Martinez","year":"2011","journal-title":"Lancet"},{"issue":"26","key":"10.1016\/j.ccm.2013.10.003_bib5","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1056\/NEJMoa032158","article-title":"The nature of small-airway obstruction in chronic obstructive pulmonary disease","volume":"350","author":"Hogg","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"9691","key":"10.1016\/j.ccm.2013.10.003_bib6","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S0140-6736(09)61342-8","article-title":"New drugs for exacerbations of chronic obstructive pulmonary disease","volume":"374","author":"Hansel","year":"2009","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.ccm.2013.10.003_bib7","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1056\/NEJMoa1106955","article-title":"Small-airway obstruction and emphysema in chronic obstructive pulmonary disease","volume":"365","author":"McDonough","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"9795","key":"10.1016\/j.ccm.2013.10.003_bib8","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/S0140-6736(11)60988-4","article-title":"New insights into the immunology of chronic obstructive pulmonary disease","volume":"378","author":"Brusselle","year":"2011","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ccm.2013.10.003_bib9","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1513\/pats.200903-012DS","article-title":"Testing drugs in animal models of cigarette smoke-induced chronic obstructive pulmonary disease","volume":"6","author":"Churg","year":"2009","journal-title":"Proc Am Thorac Soc"},{"issue":"8","key":"10.1016\/j.ccm.2013.10.003_bib10","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/thx.2003.012468","article-title":"Acute effects of cigarette smoke on inflammation and oxidative stress: a review","volume":"59","author":"van der Vaart","year":"2004","journal-title":"Thorax"},{"issue":"3","key":"10.1016\/j.ccm.2013.10.003_bib11","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1183\/09031936.04.00012704","article-title":"The impact of smoking cessation on respiratory symptoms, lung function, airway hyperresponsiveness and inflammation","volume":"23","author":"Willemse","year":"2004","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.ccm.2013.10.003_bib12","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1183\/09031936.05.00108904","article-title":"Effect of 1-year smoking cessation on airway inflammation in COPD and asymptomatic smokers","volume":"26","author":"Willemse","year":"2005","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.ccm.2013.10.003_bib13","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.coph.2006.11.015","article-title":"Models of infection and exacerbations in COPD","volume":"7","author":"Papi","year":"2007","journal-title":"Curr Opin Pharmacol"},{"issue":"9589","key":"10.1016\/j.ccm.2013.10.003_bib14","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S0140-6736(07)61381-6","article-title":"What have we learned from large drug treatment trials in COPD?","volume":"370","author":"Calverley","year":"2007","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.ccm.2013.10.003_bib15","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1056\/NEJMoa1105482","article-title":"Changes in forced expiratory volume in 1 second over time in COPD","volume":"365","author":"Vestbo","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl","key":"10.1016\/j.ccm.2013.10.003_bib16","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1749-6632.1991.tb55336.x","article-title":"Design of a clinical trial to test a treatment of the underlying cause of emphysema","volume":"624","author":"Anthonisen","year":"1991","journal-title":"Ann N Y Acad Sci"},{"issue":"5","key":"10.1016\/j.ccm.2013.10.003_bib17","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1164\/rccm.200912-1843CC","article-title":"Chronic obstructive pulmonary disease phenotypes: the future of COPD","volume":"182","author":"Han","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"issue":"15","key":"10.1016\/j.ccm.2013.10.003_bib18","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1056\/NEJMoa11798","article-title":"Patients at high risk of death after lung-volume-reduction surgery","volume":"345","author":"National Emphysema Treatment Trial Research Group","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccm.2013.10.003_bib19","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/1465-9921-11-122","article-title":"Characterisation of COPD heterogeneity in the ECLIPSE cohort","volume":"11","author":"Agusti","year":"2010","journal-title":"Respir Res"},{"issue":"9","key":"10.1016\/j.ccm.2013.10.003_bib20","doi-asserted-by":"crossref","first-page":"e24395","DOI":"10.1371\/journal.pone.0024395","article-title":"Genetics of sputum gene expression in chronic obstructive pulmonary disease","volume":"6","author":"Qiu","year":"2011","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.ccm.2013.10.003_bib21","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.rmed.2011.02.009","article-title":"Evaluation of exhaled breath condensate pH as a biomarker for COPD","volume":"105","author":"MacNee","year":"2011","journal-title":"Respir Med"},{"issue":"4","key":"10.1016\/j.ccm.2013.10.003_bib22","doi-asserted-by":"crossref","first-page":"047101","DOI":"10.1088\/1752-7155\/6\/4\/047101","article-title":"Review of exhaled nitric oxide in chronic obstructive pulmonary disease","volume":"6","author":"Gelb","year":"2012","journal-title":"J\u00a0Breath Res"},{"key":"10.1016\/j.ccm.2013.10.003_bib23","doi-asserted-by":"crossref","DOI":"10.1002\/elps.201300020","article-title":"Proteomic analysis of human epithelial lining fluid by microfluidics-based nanoLC-MS\/MS: a feasibility study","author":"Franciosi","year":"2013","journal-title":"Electrophoresis"},{"issue":"9","key":"10.1016\/j.ccm.2013.10.003_bib24","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1164\/rccm.201208-1449OC","article-title":"A\u00a0dynamic bronchial airway gene expression signature of chronic obstructive pulmonary disease and lung function impairment","volume":"187","author":"Steiling","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.ccm.2013.10.003_bib25","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1513\/pats.201101-015RM","article-title":"Novel outcomes and end points: biomarkers in chronic obstructive pulmonary disease clinical trials","volume":"8","author":"Woodruff","year":"2011","journal-title":"Proc Am Thorac Soc"},{"issue":"12","key":"10.1016\/j.ccm.2013.10.003_bib26","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1164\/rccm.201010-1623OC","article-title":"Identification of novel diagnostic biomarkers for asthma and chronic obstructive pulmonary disease","volume":"183","author":"Verrills","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.ccm.2013.10.003_bib27","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.trsl.2012.01.019","article-title":"Biomarkers in chronic obstructive pulmonary disease","volume":"159","author":"Rosenberg","year":"2012","journal-title":"Transl Res"},{"issue":"2 Pt 1","key":"10.1016\/j.ccm.2013.10.003_bib28","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1164\/ajrccm.161.2.9901044","article-title":"Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The lung health study","volume":"161","author":"Scanlon","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.ccm.2013.10.003_bib29","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1183\/09031936.00060806","article-title":"Smoking cessation in patients with respiratory diseases: a high priority, integral component of therapy","volume":"29","author":"Tonnesen","year":"2007","journal-title":"Eur Respir J"},{"issue":"10","key":"10.1016\/j.ccm.2013.10.003_bib30","article-title":"Combined pharmacotherapy and behavioural interventions for smoking cessation","author":"Stead","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.ccm.2013.10.003_bib31","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/j.1365-2362.2011.02598.x","article-title":"Validity of HMGB1 measurement in epithelial lining fluid in patients with COPD","volume":"42","author":"Kanazawa","year":"2012","journal-title":"Eur J Clin Invest"},{"issue":"11","key":"10.1016\/j.ccm.2013.10.003_bib32","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1517\/14656566.2011.587121","article-title":"Varenicline for tobacco dependence: panacea or plight?","volume":"12","author":"Williams","year":"2011","journal-title":"Expert Opin Pharmacother"},{"issue":"13","key":"10.1016\/j.ccm.2013.10.003_bib33","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa1102035","article-title":"Placebo-controlled trial of cytisine for smoking cessation","volume":"365","author":"West","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.ccm.2013.10.003_bib34","article-title":"Nicotine vaccines for smoking cessation","author":"Hartmann-Boyce","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.ccm.2013.10.003_bib35","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1002\/jps.23465","article-title":"Back to the future: inhaled drug products","volume":"102","author":"Hickey","year":"2013","journal-title":"J\u00a0Pharm Sci"},{"issue":"1","key":"10.1016\/j.ccm.2013.10.003_bib36","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.lungcan.2010.07.016","article-title":"Bronchoscopic microsampling is a useful complementary diagnostic tool for detecting lung cancer","volume":"72","author":"Yasuda","year":"2011","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.ccm.2013.10.003_bib37","first-page":"4","article-title":"Neuronal mechanisms underlying development of nicotine dependence: implications for novel smoking-cessation treatments","volume":"6","author":"D'Souza","year":"2011","journal-title":"Addict Sci Clin Pract"},{"issue":"3","key":"10.1016\/j.ccm.2013.10.003_bib38","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1183\/09031936.00213711","article-title":"Emerging anti-inflammatory strategies for COPD","volume":"40","author":"Cazzola","year":"2012","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.ccm.2013.10.003_bib39","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1124\/pr.111.004580","article-title":"Pharmacology and therapeutics of bronchodilators","volume":"64","author":"Cazzola","year":"2012","journal-title":"Pharmacol Rev"},{"issue":"7","key":"10.1016\/j.ccm.2013.10.003_bib40","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1164\/rccm.201209-1739PP","article-title":"Beta2-agonist therapy in lung disease","volume":"187","author":"Cazzola","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.ccm.2013.10.003_bib41","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.pupt.2012.12.006","article-title":"Long-acting muscarinic receptor antagonists for the treatment of respiratory disease","volume":"26","author":"Cazzola","year":"2013","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.ccm.2013.10.003_bib42","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1465-9921-11-135","article-title":"Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium","volume":"11","author":"Vogelmeier","year":"2010","journal-title":"Respir Res"},{"issue":"3","key":"10.1016\/j.ccm.2013.10.003_bib43","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.pupt.2010.01.003","article-title":"Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design","volume":"23","author":"Barnes","year":"2010","journal-title":"Pulm Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.ccm.2013.10.003_bib44","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.rmed.2011.02.008","article-title":"Indacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: a 12-week study","volume":"105","author":"Korn","year":"2011","journal-title":"Respir Med"},{"issue":"5","key":"10.1016\/j.ccm.2013.10.003_bib45","first-page":"482","article-title":"Aclidinium bromide, a novel long-acting muscarinic M3 antagonist for the treatment of COPD","volume":"10","author":"Cazzola","year":"2009","journal-title":"Curr Opin Investig Drugs"},{"issue":"6","key":"10.1016\/j.ccm.2013.10.003_bib46","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1517\/14656566.2013.776539","article-title":"Aclidinium bromide\/formoterol fumarate fixed-dose combination for the treatment of chronic obstructive pulmonary disease","volume":"14","author":"Cazzola","year":"2013","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.ccm.2013.10.003_bib47","doi-asserted-by":"crossref","first-page":"729","DOI":"10.2147\/COPD.S36001","article-title":"Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD","volume":"7","author":"Buhl","year":"2012","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"5","key":"10.1016\/j.ccm.2013.10.003_bib48","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1183\/09031936.00040712","article-title":"Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study","volume":"40","author":"Kerwin","year":"2012","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ccm.2013.10.003_bib49","doi-asserted-by":"crossref","first-page":"503","DOI":"10.2147\/COPD.S32451","article-title":"Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial","volume":"7","author":"Beeh","year":"2012","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"7","key":"10.1016\/j.ccm.2013.10.003_bib50","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.rmed.2010.02.017","article-title":"Combining tiotropium and salmeterol in COPD: effects on airflow obstruction and symptoms","volume":"104","author":"van Noord","year":"2010","journal-title":"Respir Med"},{"issue":"3","key":"10.1016\/j.ccm.2013.10.003_bib51","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1378\/chest.129.3.509","article-title":"Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD","volume":"129","author":"van Noord","year":"2006","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.ccm.2013.10.003_bib52","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/15412550902724073","article-title":"Formoterol and tiotropium compared with tiotropium alone for treatment of COPD","volume":"6","author":"Tashkin","year":"2009","journal-title":"COPD"},{"issue":"12","key":"10.1016\/j.ccm.2013.10.003_bib53","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1136\/thx.2010.139113","article-title":"QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease","volume":"65","author":"van Noord","year":"2010","journal-title":"Thorax"},{"issue":"Suppl A","key":"10.1016\/j.ccm.2013.10.003_bib54","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S0954-6111(03)80010-0","article-title":"Dual dopamine D2 receptor and beta2-adrenoceptor agonists for the treatment of chronic obstructive pulmonary disease: the pre-clinical rationale","volume":"97","author":"Dougall","year":"2003","journal-title":"Respir Med"},{"issue":"Suppl A","key":"10.1016\/j.ccm.2013.10.003_bib55","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/S0954-6111(03)80014-8","article-title":"Long-term use of Viozan (sibenadet HCl) in patients with chronic obstructive pulmonary disease: results of a 1-year study","volume":"97","author":"Hiller","year":"2003","journal-title":"Respir Med"},{"issue":"4","key":"10.1016\/j.ccm.2013.10.003_bib56","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1164\/rccm.201204-0596PP","article-title":"Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary","volume":"187","author":"Vestbo","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.ccm.2013.10.003_bib57","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s00408-011-9289-0","article-title":"Inappropriate overuse of inhaled corticosteroids for COPD patients: impact on health costs and health status","volume":"189","author":"de Miguel-Diez","year":"2011","journal-title":"Lung"},{"issue":"7","key":"10.1016\/j.ccm.2013.10.003_bib58","article-title":"Inhaled corticosteroids for stable chronic obstructive pulmonary disease","author":"Yang","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ccm.2013.10.003_bib59","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1164\/rccm.200707-973OC","article-title":"The prevention of COPD exacerbations by salmeterol\/fluticasone propionate or tiotropium bromide","volume":"177","author":"Wedzicha","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.ccm.2013.10.003_bib60","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1182\/blood-2006-02-001115","article-title":"Glucocorticoids induce differentiation of a specifically activated, anti-inflammatory subtype of human monocytes","volume":"109","author":"Ehrchen","year":"2007","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ccm.2013.10.003_bib61","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1476-5381.2010.01199.x","article-title":"Glucocorticosteroids: current and future directions","volume":"163","author":"Barnes","year":"2011","journal-title":"Br J Pharmacol"},{"issue":"5","key":"10.1016\/j.ccm.2013.10.003_bib62","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.pupt.2006.06.001","article-title":"A\u00a0pilot study to assess the effects of combining fluticasone propionate\/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD","volume":"20","author":"Cazzola","year":"2007","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.ccm.2013.10.003_bib63","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1136\/thx.2007.087213","article-title":"Superiority of \u201ctriple\u201d therapy with salmeterol\/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD","volume":"63","author":"Singh","year":"2008","journal-title":"Thorax"},{"key":"10.1016\/j.ccm.2013.10.003_bib64","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1465-9921-12-54","article-title":"Characterization of the bronchodilatory dose response to indacaterol in patients with chronic obstructive pulmonary disease using model-based approaches","volume":"12","author":"Renard","year":"2011","journal-title":"Respir Res"},{"issue":"19","key":"10.1016\/j.ccm.2013.10.003_bib65","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1056\/NEJMoa041892","article-title":"Decreased histone deacetylase activity in chronic obstructive pulmonary disease","volume":"352","author":"Ito","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.ccm.2013.10.003_bib66","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1164\/rccm.200810-1570OC","article-title":"Inhibition of PI3Kdelta restores glucocorticoid function in smoking-induced airway inflammation in mice","volume":"179","author":"Marwick","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.ccm.2013.10.003_bib67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/jpet.106.111674","article-title":"Therapeutic potential of phosphatidylinositol 3-kinase inhibitors in inflammatory respiratory disease","volume":"321","author":"Ito","year":"2007","journal-title":"J\u00a0Pharmacol Exp Ther"},{"issue":"2","key":"10.1016\/j.ccm.2013.10.003_bib68","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2012-002178","article-title":"Acute and chronic inflammatory responses induced by smoking in individuals susceptible and non-susceptible to development of COPD: from specific disease phenotyping towards novel therapy. Protocol of a cross-sectional study","volume":"3","author":"Lo Tam Loi","year":"2013","journal-title":"BMJ Open"},{"issue":"5","key":"10.1016\/j.ccm.2013.10.003_bib69","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1136\/thx.2008.103432","article-title":"Low-dose theophylline enhances the anti-inflammatory effects of steroids during exacerbations of COPD","volume":"64","author":"Cosio","year":"2009","journal-title":"Thorax"},{"issue":"5","key":"10.1016\/j.ccm.2013.10.003_bib70","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1084\/jem.20040416","article-title":"Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages","volume":"200","author":"Cosio","year":"2004","journal-title":"J\u00a0Exp Med"},{"issue":"3","key":"10.1016\/j.ccm.2013.10.003_bib71","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1183\/09031936.00014012","article-title":"Smoking cessation strategies in patients with COPD","volume":"41","author":"Warnier","year":"2013","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ccm.2013.10.003_bib72","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1164\/ajrccm.164.3.2010017","article-title":"Lower respiratory illnesses promote FEV1 decline in current smokers but not ex-smokers with chronic obstructive pulmonary disease: results from Lung Health Study","volume":"164","author":"Kanner","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"10.1016\/j.ccm.2013.10.003_bib73","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1136\/thorax.57.10.847","article-title":"Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease","volume":"57","author":"Donaldson","year":"2002","journal-title":"Thorax"},{"issue":"3","key":"10.1016\/j.ccm.2013.10.003_bib74","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/01.qco.0000224815.89363.15","article-title":"The role of bacteria in airway inflammation in exacerbations of chronic obstructive pulmonary disease","volume":"19","author":"Murphy","year":"2006","journal-title":"Curr Opin Infect Dis"},{"issue":"9","key":"10.1016\/j.ccm.2013.10.003_bib75","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1164\/rccm.200509-1525OC","article-title":"Airway inflammation and bronchial bacterial colonization in chronic obstructive pulmonary disease","volume":"173","author":"Sethi","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"10.1016\/j.ccm.2013.10.003_bib76","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1136\/thorax.57.9.759","article-title":"Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations","volume":"57","author":"Patel","year":"2002","journal-title":"Thorax"},{"issue":"11","key":"10.1016\/j.ccm.2013.10.003_bib77","doi-asserted-by":"crossref","first-page":"3546","DOI":"10.1172\/JCI36130","article-title":"The cytokine network in asthma and chronic obstructive pulmonary disease","volume":"118","author":"Barnes","year":"2008","journal-title":"J\u00a0Clin Invest"},{"issue":"2","key":"10.1016\/j.ccm.2013.10.003_bib78","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/MCP.0b013e3282f37a11","article-title":"Prevalence and outcome of severe chronic obstructive pulmonary disease exacerbations caused by multidrug-resistant bacteria","volume":"14","author":"Nseir","year":"2008","journal-title":"Curr Opin Pulm Med"},{"issue":"2","key":"10.1016\/j.ccm.2013.10.003_bib79","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ijantimicag.2007.04.006","article-title":"Bacteriophages: an appraisal of their role in the treatment of bacterial infections","volume":"30","author":"Hanlon","year":"2007","journal-title":"Int J Antimicrob Agents"},{"issue":"5","key":"10.1016\/j.ccm.2013.10.003_bib80","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nri2294","article-title":"Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators","volume":"8","author":"Serhan","year":"2008","journal-title":"Nat Rev Immunol"},{"issue":"Suppl 9A","key":"10.1016\/j.ccm.2013.10.003_bib81","first-page":"5S","article-title":"Clinical implications of the immunomodulatory effects of macrolides","volume":"117","author":"Tamaoki","year":"2004","journal-title":"Am J Med"},{"issue":"3","key":"10.1016\/j.ccm.2013.10.003_bib82","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1128\/CMR.00078-09","article-title":"Mechanisms of action and clinical application of macrolides as immunomodulatory medications","volume":"23","author":"Kanoh","year":"2010","journal-title":"Clin Microbiol Rev"},{"issue":"8","key":"10.1016\/j.ccm.2013.10.003_bib83","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1056\/NEJMoa1104623","article-title":"Azithromycin for prevention of exacerbations of COPD","volume":"365","author":"Albert","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.ccm.2013.10.003_bib84","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1164\/rccm.200801-145OC","article-title":"Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations","volume":"178","author":"Seemungal","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ccm.2013.10.003_bib85","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1465-9921-7-16","article-title":"EM703 improves bleomycin-induced pulmonary fibrosis in mice by the inhibition of TGF-beta signaling in lung fibroblasts","volume":"7","author":"Li","year":"2006","journal-title":"Respir Res"},{"key":"10.1016\/j.ccm.2013.10.003_bib86","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1465-9921-11-10","article-title":"Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial","volume":"11","author":"Sethi","year":"2010","journal-title":"Respir Res"},{"issue":"2","key":"10.1016\/j.ccm.2013.10.003_bib87","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/MCP.0b013e3282f4a99f","article-title":"Viral infections in patients with chronic obstructive pulmonary disease","volume":"14","author":"Varkey","year":"2008","journal-title":"Curr Opin Pulm Med"},{"issue":"1","key":"10.1016\/j.ccm.2013.10.003_bib88","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/MOP.0b013e3282f41cb6","article-title":"New developments in the epidemiology and clinical spectrum of rhinovirus infections","volume":"20","author":"Brownlee","year":"2008","journal-title":"Curr Opin Pediatr"},{"issue":"1","key":"10.1016\/j.ccm.2013.10.003_bib89","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1183\/09031936.03.00093703","article-title":"Airway epithelial inflammatory responses and clinical parameters in COPD","volume":"22","author":"Patel","year":"2003","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ccm.2013.10.003_bib90","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1465-9921-14-15","article-title":"Novel immune genes associated with excessive inflammatory and antiviral responses to rhinovirus in COPD","volume":"14","author":"Baines","year":"2013","journal-title":"Respir Res"},{"issue":"7\u20138","key":"10.1016\/j.ccm.2013.10.003_bib91","doi-asserted-by":"crossref","first-page":"476","DOI":"10.2119\/2008-00034.Klune","article-title":"HMGB1: endogenous danger signaling","volume":"14","author":"Klune","year":"2008","journal-title":"Mol Med"},{"issue":"1","key":"10.1016\/j.ccm.2013.10.003_bib92","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1080\/15412550902724024","article-title":"Recognizing the importance of respiratory syncytial virus in chronic obstructive pulmonary disease","volume":"6","author":"Ramaswamy","year":"2009","journal-title":"COPD"},{"issue":"Suppl 10","key":"10.1016\/j.ccm.2013.10.003_bib93","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1097\/INF.0b013e3181684d67","article-title":"Respiratory syncytial virus persistence in chronic obstructive pulmonary disease","volume":"27","author":"Sikkel","year":"2008","journal-title":"Pediatr Infect Dis J"},{"issue":"2","key":"10.1016\/j.ccm.2013.10.003_bib94","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1517\/14728210902946399","article-title":"Emerging drugs for respiratory syncytial virus infection","volume":"14","author":"Olszewska","year":"2009","journal-title":"Expert Opin Emerg Drugs"},{"key":"10.1016\/j.ccm.2013.10.003_bib95","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1056\/NEJMoa0903810","article-title":"Emergence of a novel swine-origin influenza A (H1N1) virus in humans","volume":"360","author":"Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1016\/j.ccm.2013.10.003_bib96","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1056\/NEJMcp0807498","article-title":"Clinical practice. Prevention and treatment of seasonal influenza","volume":"359","author":"Glezen","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.ccm.2013.10.003_bib97","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1086\/591851","article-title":"Developing new antiviral agents for influenza treatment: what does the future hold?","volume":"48","author":"Hayden","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"2\u20133","key":"10.1016\/j.ccm.2013.10.003_bib98","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.ejphar.2008.03.009","article-title":"Cells, mediators and Toll-like receptors in COPD","volume":"585","author":"Sarir","year":"2008","journal-title":"Eur J Pharmacol"},{"issue":"8","key":"10.1016\/j.ccm.2013.10.003_bib99","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1513\/pats.200706-067TH","article-title":"Toll-like receptors, Notch ligands, and cytokines drive the chronicity of lung inflammation","volume":"4","author":"Raymond","year":"2007","journal-title":"Proc Am Thorac Soc"},{"key":"10.1016\/j.ccm.2013.10.003_bib100","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1600-065X.2008.00701.x","article-title":"The interleukin-1 receptor\/Toll-like receptor superfamily: 10 years of progress","volume":"226","author":"O'Neill","year":"2008","journal-title":"Immunol Rev"},{"issue":"1","key":"10.1016\/j.ccm.2013.10.003_bib101","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/BJ20090272","article-title":"Pathogen recognition in the innate immune response","volume":"420","author":"Kumar","year":"2009","journal-title":"Biochem J"},{"issue":"4","key":"10.1016\/j.ccm.2013.10.003_bib102","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1164\/rccm.200707-1019OC","article-title":"Toll-like receptor 2 is essential for the sensing of oxidants during inflammation","volume":"179","author":"Paul-Clark","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.ccm.2013.10.003_bib103","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1152\/japplphysiol.00172.2007","article-title":"Role of TLR2, TLR4, and MyD88 in murine ozone-induced airway hyperresponsiveness and neutrophilia","volume":"103","author":"Williams","year":"2007","journal-title":"J\u00a0Appl Physiol"},{"issue":"2","key":"10.1016\/j.ccm.2013.10.003_bib104","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.4049\/jimmunol.180.2.1169","article-title":"Cigarette smoke-induced pulmonary inflammation is TLR4\/MyD88 and IL-1R1\/MyD88 signaling dependent","volume":"180","author":"Doz","year":"2008","journal-title":"J\u00a0Immunol"},{"issue":"7","key":"10.1016\/j.ccm.2013.10.003_bib105","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/ncprheum0531","article-title":"Mechanisms of disease: a 'DAMP' view of inflammatory arthritis","volume":"3","author":"Foell","year":"2007","journal-title":"Nat Clin Pract Rheumatol"},{"issue":"1","key":"10.1016\/j.ccm.2013.10.003_bib106","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1189\/jlb.0306164","article-title":"DAMPs, PAMPs and alarmins: all we need to know about danger","volume":"81","author":"Bianchi","year":"2007","journal-title":"J\u00a0Leukoc Biol"},{"issue":"8","key":"10.1016\/j.ccm.2013.10.003_bib107","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1111\/j.1462-5822.2009.01326.x","article-title":"Scavenger receptors: role in innate immunity and microbial pathogenesis","volume":"11","author":"Areschoug","year":"2009","journal-title":"Cell Microbiol"},{"issue":"3","key":"10.1016\/j.ccm.2013.10.003_bib108","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1189\/jlb.0409230","article-title":"RAGE: therapeutic target and biomarker of the inflammatory response\u2013the evidence mounts","volume":"86","author":"Ramasamy","year":"2009","journal-title":"J\u00a0Leukoc Biol"},{"issue":"3","key":"10.1016\/j.ccm.2013.10.003_bib109","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.jaci.2006.05.013","article-title":"Toll-like receptor 2, 3, and 4 expression and function in human airway smooth muscle","volume":"118","author":"Sukkar","year":"2006","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.ccm.2013.10.003_bib110","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1124\/pr.109.001073","article-title":"Therapeutic targeting of toll-like receptors for infectious and inflammatory diseases and cancer","volume":"61","author":"O'Neill","year":"2009","journal-title":"Pharmacol Rev"},{"issue":"7450","key":"10.1016\/j.ccm.2013.10.003_bib111","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/nature12118","article-title":"The TLR4 antagonist Eritoran protects mice from lethal influenza infection","volume":"497","author":"Shirey","year":"2013","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.ccm.2013.10.003_bib112","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1378\/chest.06-2869","article-title":"Reducing the toll of inflammatory lung disease","volume":"131","author":"Chaudhuri","year":"2007","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.ccm.2013.10.003_bib113","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.cyto.2008.07.010","article-title":"Signalling adaptors used by Toll-like receptors: an update","volume":"43","author":"Kenny","year":"2008","journal-title":"Cytokine"},{"issue":"Suppl 51","key":"10.1016\/j.ccm.2013.10.003_bib114","first-page":"1294","article-title":"Inhibition of LPS-induced neutrophilic inflammation in healthy volunteers","volume":"30","author":"O'Connor","year":"2007","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.ccm.2013.10.003_bib115","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1183\/09031936.00048509","article-title":"SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects","volume":"35","author":"Holz","year":"2010","journal-title":"Eur Respir J"},{"issue":"9","key":"10.1016\/j.ccm.2013.10.003_bib116","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.rmed.2010.04.010","article-title":"Tolerability and efficacy of inhaled AZD4818, a CCR1 antagonist, in moderate to severe COPD patients","volume":"104","author":"Kerstjens","year":"2010","journal-title":"Respir Med"},{"issue":"8","key":"10.1016\/j.ccm.2013.10.003_bib117","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1517\/13543784.2010.500019","article-title":"DP(2) receptor antagonists in development","volume":"19","author":"Norman","year":"2010","journal-title":"Expert Opin Investig Drugs"},{"issue":"2","key":"10.1016\/j.ccm.2013.10.003_bib118","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1378\/chest.99.2.289","article-title":"Serum leukotriene B4 levels in patients with obstructive pulmonary disease","volume":"99","author":"Seggev","year":"1991","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.ccm.2013.10.003_bib119","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1378\/chest.123.4.1240","article-title":"Neutrophil chemotactic activity of sputum from patients with COPD: role of interleukin 8 and leukotriene B4","volume":"123","author":"Beeh","year":"2003","journal-title":"Chest"},{"issue":"6000","key":"10.1016\/j.ccm.2013.10.003_bib120","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1126\/science.1190594","article-title":"A\u00a0critical role for LTA4H in limiting chronic pulmonary neutrophilic inflammation","volume":"330","author":"Snelgrove","year":"2010","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.ccm.2013.10.003_bib121","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.pupt.2012.12.003","article-title":"Inhaled pan-selectin antagonist Bimosiamose attenuates airway inflammation in COPD","volume":"26","author":"Watz","year":"2012","journal-title":"Pulm Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.ccm.2013.10.003_bib122","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1517\/13543771003767468","article-title":"Selectin inhibitors: a patent review","volume":"20","author":"Bedard","year":"2010","journal-title":"Expert Opin Ther Pat"},{"issue":"6","key":"10.1016\/j.ccm.2013.10.003_bib123","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/j.1365-2125.2008.03155.x","article-title":"Phosphodiesterase 4 inhibitors in chronic obstructive pulmonary disease: a new approach to oral treatment","volume":"65","author":"Currie","year":"2008","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.ccm.2013.10.003_bib124","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/bjp.2008.297","article-title":"Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking?","volume":"155","author":"Giembycz","year":"2008","journal-title":"Br J Pharmacol"},{"issue":"1","key":"10.1016\/j.ccm.2013.10.003_bib125","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/nyas.12039","article-title":"Targeting phosphoinositide 3-kinase delta for the treatment of respiratory diseases","volume":"1280","author":"Sriskantharajah","year":"2013","journal-title":"Ann N Y Acad Sci"},{"issue":"Suppl 2","key":"10.1016\/j.ccm.2013.10.003_bib126","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2165\/0003495-200868002-00002","article-title":"The efficacy and safety of cilomilast in COPD","volume":"68","author":"Rennard","year":"2008","journal-title":"Drugs"},{"issue":"9278","key":"10.1016\/j.ccm.2013.10.003_bib127","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0140-6736(01)05481-2","article-title":"Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study","volume":"358","author":"Compton","year":"2001","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ccm.2013.10.003_bib128","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1378\/chest.129.1.56","article-title":"Cilomilast for COPD: results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4","volume":"129","author":"Rennard","year":"2006","journal-title":"Chest"},{"issue":"9485","key":"10.1016\/j.ccm.2013.10.003_bib129","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0140-6736(05)67100-0","article-title":"Roflumilast\u2013an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial","volume":"366","author":"Rabe","year":"2005","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ccm.2013.10.003_bib130","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1164\/rccm.200610-1563OC","article-title":"Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease","volume":"176","author":"Calverley","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"issue":"9691","key":"10.1016\/j.ccm.2013.10.003_bib131","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0140-6736(09)61252-6","article-title":"Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials","volume":"374","author":"Fabbri","year":"2009","journal-title":"Lancet"},{"issue":"9691","key":"10.1016\/j.ccm.2013.10.003_bib132","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(09)61255-1","article-title":"Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials","volume":"374","author":"Calverley","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ccm.2013.10.003_bib133","first-page":"147","article-title":"Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD","volume":"4","author":"Giembycz","year":"2010","journal-title":"Drug Des Devel Ther"},{"issue":"5","key":"10.1016\/j.ccm.2013.10.003_bib134","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002309.pub3","article-title":"Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease","author":"Chong","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ccm.2013.10.003_bib135","first-page":"375","article-title":"Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? the REACT study protocol","volume":"7","author":"Calverley","year":"2012","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"7","key":"10.1016\/j.ccm.2013.10.003_bib136","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1172\/JCI0215506","article-title":"Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis","volume":"110","author":"Robichaud","year":"2002","journal-title":"J\u00a0Clin Invest"},{"issue":"10","key":"10.1016\/j.ccm.2013.10.003_bib137","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1517\/13543780903179294","article-title":"Emerging oligonucleotide therapies for asthma and chronic obstructive pulmonary disease","volume":"18","author":"Seguin","year":"2009","journal-title":"Expert Opin Investig Drugs"},{"issue":"3","key":"10.1016\/j.ccm.2013.10.003_bib138","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.jaci.2012.12.1564","article-title":"Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease","volume":"131","author":"Barnes","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.ccm.2013.10.003_bib139","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.coph.2013.02.008","article-title":"Targeting kinases: a new approach to treating inflammatory rheumatic diseases","volume":"13","author":"Simmons","year":"2013","journal-title":"Curr Opin Pharmacol"},{"issue":"6","key":"10.1016\/j.ccm.2013.10.003_bib140","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nrd2829","article-title":"Targeting innate immunity protein kinase signalling in inflammation","volume":"8","author":"Gaestel","year":"2009","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"10.1016\/j.ccm.2013.10.003_bib141","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1378\/chest.10-1914","article-title":"p38 mitogen-activated protein kinase pathways in asthma and COPD","volume":"139","author":"Chung","year":"2011","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.ccm.2013.10.003_bib142","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1177\/0091270010397050","article-title":"An oral inhibitor of p38 MAP kinase reduces plasma fibrinogen in patients with chronic obstructive pulmonary disease","volume":"52","author":"Lomas","year":"2012","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.ccm.2013.10.003_bib143","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1189\/jlb.0809544","article-title":"Abrogation of NF-kappaB signaling in human neutrophils induces neutrophil survival through sustained p38-MAPK activation","volume":"88","author":"Langereis","year":"2010","journal-title":"J\u00a0Leukoc Biol"},{"issue":"1\u20132","key":"10.1016\/j.ccm.2013.10.003_bib144","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3109\/15419061.2013.775257","article-title":"Role of transcription factors in the pathogenesis of asthma and COPD","volume":"20","author":"Caramori","year":"2013","journal-title":"Cell Commun Adhes"},{"issue":"4","key":"10.1016\/j.ccm.2013.10.003_bib145","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s11912-013-0316-6","article-title":"Exploring novel therapeutic targets in gist: focus on the PI3K\/Akt\/mTOR pathway","volume":"15","author":"Patel","year":"2013","journal-title":"Curr Oncol Rep"},{"issue":"5","key":"10.1016\/j.ccm.2013.10.003_bib146","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.jaci.2010.02.003","article-title":"A\u00a0role for phosphoinositol 3-kinase delta in the impairment of glucocorticoid responsiveness in patients with chronic obstructive pulmonary disease","volume":"125","author":"Marwick","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.ccm.2013.10.003_bib147","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.cellsig.2010.10.002","article-title":"Phosphoinositide 3-kinase delta (PI3Kdelta) in leukocyte signaling and function","volume":"23","author":"Fung-Leung","year":"2011","journal-title":"Cell Signal"},{"key":"10.1016\/j.ccm.2013.10.003_bib148","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/nyas.12029","article-title":"Phosphoinositide 3-kinase gamma in T cell biology and disease therapy","volume":"1280","author":"Fung-Leung","year":"2013","journal-title":"Ann N Y Acad Sci"},{"issue":"3","key":"10.1016\/j.ccm.2013.10.003_bib149","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1124\/jpet.108.144311","article-title":"Aerosolized phosphoinositide 3-kinase gamma\/delta inhibitor TG100-115 [3-[2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol] as a therapeutic candidate for asthma and chronic obstructive pulmonary disease","volume":"328","author":"Doukas","year":"2009","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.ccm.2013.10.003_bib150","doi-asserted-by":"crossref","first-page":"256874","DOI":"10.1155\/2012\/256874","article-title":"PPARgamma as a potential target to treat airway mucus hypersecretion in chronic airway inflammatory diseases","volume":"2012","author":"Shen","year":"2012","journal-title":"PPAR Res"},{"issue":"1","key":"10.1016\/j.ccm.2013.10.003_bib151","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ejpb.2011.10.003","article-title":"Inhalable dry-emulsion formulation of cyclosporine A with improved anti-inflammatory effects in experimental asthma\/COPD-model rats","volume":"80","author":"Onoue","year":"2012","journal-title":"Eur J Pharm Biopharm"},{"issue":"5","key":"10.1016\/j.ccm.2013.10.003_bib152","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1183\/09031936.00128008","article-title":"Systemic manifestations and comorbidities of COPD","volume":"33","author":"Barnes","year":"2009","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.ccm.2013.10.003_bib153","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1513\/pats.201108-050MS","article-title":"Systemic inflammation and comorbidities in chronic obstructive pulmonary disease","volume":"9","author":"Agusti","year":"2012","journal-title":"Proc Am Thorac Soc"},{"issue":"1","key":"10.1016\/j.ccm.2013.10.003_bib154","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1513\/pats.200410-050SF","article-title":"Cardiovascular disease in chronic obstructive pulmonary disease","volume":"2","author":"Hunninghake","year":"2005","journal-title":"Proc Am Thorac Soc"},{"issue":"8","key":"10.1016\/j.ccm.2013.10.003_bib155","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1513\/pats.200807-069TH","article-title":"Future treatments for chronic obstructive pulmonary disease and its comorbidities","volume":"5","author":"Barnes","year":"2008","journal-title":"Proc Am Thorac Soc"},{"issue":"5","key":"10.1016\/j.ccm.2013.10.003_bib156","doi-asserted-by":"crossref","first-page":"e37483","DOI":"10.1371\/journal.pone.0037483","article-title":"Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype","volume":"7","author":"Agusti","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ccm.2013.10.003_bib157","first-page":"523","article-title":"Muscle function in COPD: a complex interplay","volume":"7","author":"Donaldson","year":"2012","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"12","key":"10.1016\/j.ccm.2013.10.003_bib158","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1136\/thoraxjnl-2012-201765","article-title":"Prospects for the development of effective pharmacotherapy targeted at the skeletal muscles in chronic obstructive pulmonary disease: a translational review","volume":"67","author":"Steiner","year":"2012","journal-title":"Thorax"},{"issue":"12","key":"10.1016\/j.ccm.2013.10.003_bib159","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1038\/nrd1901","article-title":"Anti-inflammatory effects of statins: clinical evidence and basic mechanisms","volume":"4","author":"Jain","year":"2005","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"10.1016\/j.ccm.2013.10.003_bib160","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.amjcard.2008.03.038","article-title":"Effect of statin therapy on mortality in patients with peripheral arterial disease and comparison of those with versus without associated chronic obstructive pulmonary disease","volume":"102","author":"van Gestel","year":"2008","journal-title":"Am J Cardiol"},{"issue":"9","key":"10.1016\/j.ccm.2013.10.003_bib161","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1111\/j.1742-1241.2008.01731.x","article-title":"Statins may reduce episodes of exacerbation and the requirement for intubation in patients with COPD: evidence from a retrospective cohort study","volume":"62","author":"Blamoun","year":"2008","journal-title":"Int J Clin Pract"},{"issue":"4","key":"10.1016\/j.ccm.2013.10.003_bib162","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1378\/chest.06-1997","article-title":"Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins","volume":"131","author":"Frost","year":"2007","journal-title":"Chest"},{"issue":"12","key":"10.1016\/j.ccm.2013.10.003_bib163","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1016\/j.jacc.2006.04.039","article-title":"Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease","volume":"47","author":"Mancini","year":"2006","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.ccm.2013.10.003_bib164","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1183\/09031936.00106406","article-title":"Statin use is associated with reduced mortality in COPD","volume":"29","author":"Soyseth","year":"2007","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.ccm.2013.10.003_bib165","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.pupt.2012.10.008","article-title":"Statins, systemic inflammation and risk of death in COPD: the Rotterdam study","volume":"26","author":"Lahousse","year":"2012","journal-title":"Pulm Pharmacol Ther"},{"issue":"11","key":"10.1016\/j.ccm.2013.10.003_bib166","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1136\/thx.2009.116731","article-title":"COPD and cancer mortality: the influence of statins","volume":"64","author":"van Gestel","year":"2009","journal-title":"Thorax"},{"issue":"4","key":"10.1016\/j.ccm.2013.10.003_bib167","first-page":"368","article-title":"Pathogenesis of COPD. Part II. Oxidative-antioxidative imbalance","volume":"12","author":"Mak","year":"2008","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.ccm.2013.10.003_bib168","first-page":"41","article-title":"Pulmonary toxicity and environmental contamination: radicals, electron transfer, and protection by antioxidants","volume":"201","author":"Kovacic","year":"2009","journal-title":"Rev Environ Contam Toxicol"},{"key":"10.1016\/j.ccm.2013.10.003_bib169","series-title":"New drugs and targets for respiratory diseases","article-title":"Antioxidant therapeutic strategies","author":"Kirkham","year":"2009"},{"issue":"3","key":"10.1016\/j.ccm.2013.10.003_bib170","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.coph.2012.01.015","article-title":"Antioxidant pharmacological therapies for COPD","volume":"12","author":"Rahman","year":"2012","journal-title":"Curr Opin Pharmacol"},{"issue":"7000","key":"10.1016\/j.ccm.2013.10.003_bib171","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/nature02789","article-title":"Sirtuin activators mimic caloric restriction and delay ageing in metazoans","volume":"430","author":"Wood","year":"2004","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.ccm.2013.10.003_bib172","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1513\/pats.200904-022RM","article-title":"The aging immune system and its relationship to the development of chronic obstructive pulmonary disease","volume":"6","author":"Sharma","year":"2009","journal-title":"Proc Am Thorac Soc"},{"issue":"1","key":"10.1016\/j.ccm.2013.10.003_bib173","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1378\/chest.08-1419","article-title":"COPD as a disease of accelerated lung aging","volume":"135","author":"Ito","year":"2009","journal-title":"Chest"},{"key":"10.1016\/j.ccm.2013.10.003_bib174","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1196\/annals.1354.003","article-title":"Free radical theory of aging: an update: increasing the functional life span","volume":"1067","author":"Harman","year":"2006","journal-title":"Ann N Y Acad Sci"},{"issue":"12","key":"10.1016\/j.ccm.2013.10.003_bib175","doi-asserted-by":"crossref","first-page":"4147","DOI":"10.1021\/jm2002348","article-title":"Novel chalcone derivatives as potent Nrf2 activators in mice and human lung epithelial cells","volume":"54","author":"Kumar","year":"2011","journal-title":"J\u00a0Med Chem"},{"issue":"4","key":"10.1016\/j.ccm.2013.10.003_bib176","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1378\/chest.125.4.1500","article-title":"Oral N-acetylcysteine attenuates elastase-induced pulmonary emphysema in rats","volume":"125","author":"Rubio","year":"2004","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.ccm.2013.10.003_bib177","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1034\/j.1399-3003.2000.16b12.x","article-title":"The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review","volume":"16","author":"Stey","year":"2000","journal-title":"Eur Respir J"},{"issue":"9470","key":"10.1016\/j.ccm.2013.10.003_bib178","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/S0140-6736(05)66456-2","article-title":"Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial","volume":"365","author":"Decramer","year":"2005","journal-title":"Lancet"},{"issue":"9629","key":"10.1016\/j.ccm.2013.10.003_bib179","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1016\/S0140-6736(08)60869-7","article-title":"Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study","volume":"371","author":"Zheng","year":"2008","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ccm.2013.10.003_bib180","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.freeradbiomed.2009.04.014","article-title":"GYY4137, a novel hydrogen sulfide-releasing molecule, protects against endotoxic shock in the rat","volume":"47","author":"Li","year":"2009","journal-title":"Free Radic Biol Med"},{"issue":"9","key":"10.1016\/j.ccm.2013.10.003_bib181","first-page":"1176","article-title":"Mucoactive agents for airway mucus hypersecretory diseases","volume":"52","author":"Rogers","year":"2007","journal-title":"Respir Care"},{"issue":"4","key":"10.1016\/j.ccm.2013.10.003_bib182","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1183\/09031936.00040208","article-title":"Polymorphic variation in surfactant protein B is associated with COPD exacerbations","volume":"32","author":"Foreman","year":"2008","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ccm.2013.10.003_bib183","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1177\/106002809603000616","article-title":"Dornase in treatment of chronic bronchitis","volume":"30","author":"Hudson","year":"1996","journal-title":"Ann Pharmacother"},{"issue":"3","key":"10.1016\/j.ccm.2013.10.003_bib184","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1185\/03007995.2010.548750","article-title":"The role of augmentation therapy in alpha-1 antitrypsin deficiency","volume":"27","author":"Kueppers","year":"2011","journal-title":"Curr Med Res Opin"},{"issue":"27","key":"10.1016\/j.ccm.2013.10.003_bib185","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa0904006","article-title":"MMP12, lung function, and COPD in high-risk populations","volume":"361","author":"Hunninghake","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.ccm.2013.10.003_bib186","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1124\/pr.110.002733","article-title":"Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases","volume":"62","author":"Korkmaz","year":"2010","journal-title":"Pharmacol Rev"},{"issue":"1","key":"10.1016\/j.ccm.2013.10.003_bib187","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1124\/jpet.111.182139","article-title":"AZD9668: pharmacological characterization of a novel oral inhibitor of neutrophil elastase","volume":"339","author":"Stevens","year":"2011","journal-title":"J\u00a0Pharmacol Exp Ther"},{"issue":"2","key":"10.1016\/j.ccm.2013.10.003_bib188","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3109\/15412555.2011.641803","article-title":"A\u00a0randomised, placebo-controlled, dose-finding study of AZD9668, an oral inhibitor of neutrophil elastase, in patients with chronic obstructive pulmonary disease treated with tiotropium","volume":"9","author":"Vogelmeier","year":"2012","journal-title":"COPD"},{"issue":"4","key":"10.1016\/j.ccm.2013.10.003_bib189","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/sj.bjp.0705291","article-title":"Effects of heparin and related molecules upon neutrophil aggregation and elastase release in\u00a0vitro","volume":"139","author":"Brown","year":"2003","journal-title":"Br J Pharmacol"},{"issue":"1","key":"10.1016\/j.ccm.2013.10.003_bib190","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1183\/09031936.00121611","article-title":"Series \u201cmatrix metalloproteinases in lung health and disease\u201d: matrix metalloproteinases in COPD","volume":"39","author":"Churg","year":"2012","journal-title":"Eur Respir J"},{"issue":"12","key":"10.1016\/j.ccm.2013.10.003_bib191","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1038\/sj.bjc.6600310","article-title":"Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial","volume":"86","author":"Bramhall","year":"2002","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.ccm.2013.10.003_bib192","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.pupt.2011.05.003","article-title":"Safety and tolerability of an oral MMP-9 and -12 inhibitor, AZD1236, in patients with moderate-to-severe COPD: a randomised controlled 6-week trial","volume":"24","author":"Magnussen","year":"2011","journal-title":"Pulm Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.ccm.2013.10.003_bib193","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.pupt.2011.12.011","article-title":"Effects of an oral MMP-9 and -12 inhibitor, AZD1236, on biomarkers in moderate\/severe COPD: a randomised controlled trial","volume":"25","author":"Dahl","year":"2012","journal-title":"Pulm Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.ccm.2013.10.003_bib194","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/nrd2958","article-title":"Strategies for treating idiopathic pulmonary fibrosis","volume":"9","author":"du Bois","year":"2010","journal-title":"Nat Rev Drug Discov"},{"issue":"9842","key":"10.1016\/j.ccm.2013.10.003_bib195","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/S0140-6736(12)61144-1","article-title":"New cellular and molecular mechanisms of lung injury and fibrosis in idiopathic pulmonary fibrosis","volume":"380","author":"Fernandez","year":"2012","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.ccm.2013.10.003_bib196","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1097\/MCP.0b013e328356800f","article-title":"Into the matrix: targeting fibroblasts in pulmonary fibrosis","volume":"18","author":"Sivakumar","year":"2012","journal-title":"Curr Opin Pulm Med"},{"issue":"1","key":"10.1016\/j.ccm.2013.10.003_bib197","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1476-5381.2011.01247.x","article-title":"Novel therapeutic approaches for pulmonary fibrosis","volume":"163","author":"Datta","year":"2011","journal-title":"Br J Pharmacol"},{"issue":"5","key":"10.1016\/j.ccm.2013.10.003_bib198","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1183\/09031936.00073012","article-title":"The pathogenesis of pulmonary fibrosis: a moving target","volume":"41","author":"Wuyts","year":"2013","journal-title":"Eur Respir J"},{"issue":"119","key":"10.1016\/j.ccm.2013.10.003_bib199","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1038\/ki.2010.418","article-title":"Mechanistic connection between inflammation and fibrosis","author":"Lee","year":"2010","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.ccm.2013.10.003_bib200","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1465-9921-13-3","article-title":"The pathogenesis of COPD and IPF: distinct horns of the same devil?","volume":"13","author":"Chilosi","year":"2012","journal-title":"Respir Res"},{"issue":"2","key":"10.1016\/j.ccm.2013.10.003_bib201","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/mi.2008.85","article-title":"Pulmonary fibrosis: pathogenesis, etiology and regulation","volume":"2","author":"Wilson","year":"2009","journal-title":"Mucosal Immunol"},{"issue":"3","key":"10.1016\/j.ccm.2013.10.003_bib202","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1513\/pats.200710-159DR","article-title":"Escape from the matrix: multiple mechanisms for fibroblast activation in pulmonary fibrosis","volume":"5","author":"Laurent","year":"2008","journal-title":"Proc Am Thorac Soc"},{"issue":"4","key":"10.1016\/j.ccm.2013.10.003_bib203","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1378\/chest.06-2568","article-title":"Molecular targets in pulmonary fibrosis: the myofibroblast in focus","volume":"132","author":"Scotton","year":"2007","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.ccm.2013.10.003_bib204","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMoa062382","article-title":"A\u00a0human interleukin-12\/23 monoclonal antibody for the treatment of psoriasis","volume":"356","author":"Krueger","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.ccm.2013.10.003_bib205","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1136\/thoraxjnl-2012-201761","article-title":"Epithelial to mesenchymal transition is increased in patients with COPD and induced by cigarette smoke","volume":"68","author":"Milara","year":"2013","journal-title":"Thorax"},{"issue":"2","key":"10.1016\/j.ccm.2013.10.003_bib206","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1124\/jpet.106.109314","article-title":"Effect of transforming growth factor-beta receptor I kinase inhibitor 2,4-disubstituted pteridine (SD-208) in chronic allergic airway inflammation and remodeling","volume":"319","author":"Leung","year":"2006","journal-title":"J\u00a0Pharmacol Exp Ther"},{"issue":"1","key":"10.1016\/j.ccm.2013.10.003_bib207","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.pupt.2007.03.003","article-title":"TNF-alpha antagonists and the prevention of hospitalisation for chronic obstructive pulmonary disease","volume":"21","author":"Suissa","year":"2008","journal-title":"Pulm Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.ccm.2013.10.003_bib208","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1164\/rccm.200607-995OC","article-title":"The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease","volume":"175","author":"Rennard","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"10.1016\/j.ccm.2013.10.003_bib209","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1164\/rccm.200702-253ED","article-title":"Unexpected failure of anti-tumor necrosis factor therapy in chronic obstructive pulmonary disease","volume":"175","author":"Barnes","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ccm.2013.10.003_bib210","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1465-9921-13-12","article-title":"Systemic inflammatory profile and response to anti-tumor necrosis factor therapy in chronic obstructive pulmonary disease","volume":"13","author":"Loza","year":"2012","journal-title":"Respir Res"},{"key":"10.1016\/j.ccm.2013.10.003_bib211","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1164\/rccm.200809-1512OC","article-title":"A\u00a0randomized, double-blind, placebo-controlled study of TNF-alpha blockade in severe persistent asthma","volume":"179","author":"Wenzel","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"10.1016\/j.ccm.2013.10.003_bib212","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1358\/dot.2006.42.9.1025692","article-title":"Tocilizumab: blockade of interleukin-6 signaling pathway as a therapeutic strategy for inflammatory disorders","volume":"42","author":"Paul-Pletzer","year":"2006","journal-title":"Drugs Today (Barc)"},{"issue":"1","key":"10.1016\/j.ccm.2013.10.003_bib213","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4161\/mabs.2.1.10328","article-title":"Canakinumab","volume":"2","author":"Dhimolea","year":"2010","journal-title":"MAbs"},{"key":"10.1016\/j.ccm.2013.10.003_bib214","series-title":"New drugs and targets for respiratory diseases","article-title":"Targeting interleukin-17 in the lungs","author":"Ivanov","year":"2009"},{"issue":"3","key":"10.1016\/j.ccm.2013.10.003_bib215","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.pupt.2008.12.005","article-title":"IL-17-producing T lymphocytes in lung tissue and in the bronchoalveolar space after exposure to endotoxin from Escherichia coli in\u00a0vivo\u2013effects of anti-inflammatory pharmacotherapy","volume":"22","author":"Prause","year":"2009","journal-title":"Pulm Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.ccm.2013.10.003_bib216","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1183\/09031936.00017911","article-title":"Interleukin-17A induces glucocorticoid insensitivity in human bronchial epithelial cells","volume":"39","author":"Zijlstra","year":"2012","journal-title":"Eur Respir J"},{"issue":"13","key":"10.1016\/j.ccm.2013.10.003_bib217","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1056\/NEJMoa1109997","article-title":"Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis","volume":"366","author":"Leonardi","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"10.1016\/j.ccm.2013.10.003_bib218","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1056\/NEJMoa1109017","article-title":"Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis","volume":"366","author":"Papp","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccm.2013.10.003_bib219","doi-asserted-by":"crossref","first-page":"641","DOI":"10.2147\/COPD.S28250","article-title":"Geroprotectors as a novel therapeutic strategy for COPD, an accelerating aging disease","volume":"7","author":"Ito","year":"2012","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"10","key":"10.1016\/j.ccm.2013.10.003_bib220","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.bcp.2012.06.031","article-title":"Perspectives on translational and therapeutic aspects of SIRT1 in inflammaging and senescence","volume":"84","author":"Yao","year":"2012","journal-title":"Biochem Pharmacol"},{"issue":"7","key":"10.1016\/j.ccm.2013.10.003_bib221","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1039\/c3mb00001j","article-title":"Sirtuin 6: a review of biological effects and potential therapeutic properties","volume":"9","author":"Beauharnois","year":"2013","journal-title":"Mol Biosyst"},{"issue":"10","key":"10.1016\/j.ccm.2013.10.003_bib222","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1136\/thorax.58.10.832","article-title":"Hypothesis: does COPD have an autoimmune component?","volume":"58","author":"Agusti","year":"2003","journal-title":"Thorax"},{"issue":"5","key":"10.1016\/j.ccm.2013.10.003_bib223","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/nm1583","article-title":"Antielastin autoimmunity in tobacco smoking-induced emphysema","volume":"13","author":"Lee","year":"2007","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.ccm.2013.10.003_bib224","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1164\/rccm.200701-014OC","article-title":"Autoantibodies in patients with chronic obstructive pulmonary disease","volume":"177","author":"Feghali-Bostwick","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"issue":"19","key":"10.1016\/j.ccm.2013.10.003_bib225","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1056\/NEJMoa0907441","article-title":"Maternal vitamin A supplementation and lung function in offspring","volume":"362","author":"Checkley","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.ccm.2013.10.003_bib226","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1203983","article-title":"Evidence for adult lung growth in humans","volume":"367","author":"Butler","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.ccm.2013.10.003_bib227","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1513\/pats.201102-019RM","article-title":"Rationale and emerging approaches for targeting lung repair and regeneration in the treatment of chronic obstructive pulmonary disease","volume":"8","author":"Rennard","year":"2011","journal-title":"Proc Am Thorac Soc"},{"issue":"1","key":"10.1016\/j.ccm.2013.10.003_bib228","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.1476-5381.2011.01246.x","article-title":"Is a regenerative approach viable for the treatment of COPD?","volume":"163","author":"Hind","year":"2011","journal-title":"Br J Pharmacol"},{"issue":"8","key":"10.1016\/j.ccm.2013.10.003_bib229","doi-asserted-by":"crossref","first-page":"627","DOI":"10.5966\/sctm.2012-0065","article-title":"Concise review: clinical prospects for treating chronic obstructive pulmonary disease with regenerative approaches","volume":"1","author":"Kubo","year":"2012","journal-title":"Stem Cells Transl Med"},{"issue":"6","key":"10.1016\/j.ccm.2013.10.003_bib230","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/nm0697-675","article-title":"Retinoic acid treatment abrogates elastase-induced pulmonary emphysema in rats","volume":"3","author":"Massaro","year":"1997","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.ccm.2013.10.003_bib231","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1378\/chest.130.5.1334","article-title":"Feasibility of retinoids for the treatment of emphysema study","volume":"130","author":"Roth","year":"2006","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.ccm.2013.10.003_bib232","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1183\/09031936.00161911","article-title":"Randomised controlled trial for emphysema with a selective agonist of the gamma-type retinoic acid receptor","volume":"40","author":"Stolk","year":"2012","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.ccm.2013.10.003_bib233","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1136\/thoraxjnl-2012-201923","article-title":"Mesenchymal stem cells","volume":"67","author":"Rankin","year":"2012","journal-title":"Thorax"},{"issue":"6","key":"10.1016\/j.ccm.2013.10.003_bib234","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1378\/chest.12-2094","article-title":"A\u00a0placebo-controlled, randomized trial of mesenchymal stem cells in COPD","volume":"143","author":"Weiss","year":"2013","journal-title":"Chest"},{"issue":"9819","key":"10.1016\/j.ccm.2013.10.003_bib235","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S0140-6736(12)60073-7","article-title":"Engineered whole organs and complex tissues","volume":"379","author":"Badylak","year":"2012","journal-title":"Lancet"}],"container-title":["Clinics in Chest Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272523113001457?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272523113001457?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:51:38Z","timestamp":1759452698000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272523113001457"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":235,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S0272523113001457"],"URL":"https:\/\/doi.org\/10.1016\/j.ccm.2013.10.003","relation":{},"ISSN":["0272-5231"],"issn-type":[{"value":"0272-5231","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New Drug Therapies for COPD","name":"articletitle","label":"Article Title"},{"value":"Clinics in Chest Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccm.2013.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}